Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2001 Feb;60(2):133–139. doi: 10.1136/ard.60.2.133

Increased peripheral T cell reactivity to microbial antigens and collagen type II in rheumatoid arthritis after treatment with soluble TNFα receptors

L Berg 1, J Lampa 1, S Rogberg 1, R van Vollenhoven 1, L Klareskog 1
PMCID: PMC1753474  PMID: 11156546

Abstract

OBJECTIVE—Peripheral T cells from patients with rheumatoid arthritis (RA) are hyporesponsive when stimulated with antigen or mitogen in vitro, possibly owing to increased production of proinflammatory cytokines such as tumour necrosis factor α (TNFα). This study sought to find out if and how RA T cell reactivity is affected during treatment with etanercept (Enbrel), a soluble TNFα receptor.
METHODS—Heparinised blood was collected from patients with RA at baseline, after four and eight weeks of etanercept treatment, and from healthy controls. After density separation spontaneous production of interferon γ (IFNγ), TNFα, interleukin 6 (IL6), and IL10 by peripheral blood mononuclear cells (PBMC) was detected by ELISPOT. For detection of T cell reactivity, PBMC were stimulated in vitro with mitogen (phytohaemagglutinin (PHA)), microbial antigens (purified protein derivative (PPD), influenza), or an autoantigen, collagen type II (CII). Supernatants were analysed for IFNγ and IL2 content by enzyme linked immunosorbent assay (ELISA).
RESULTS—In RA the number of cells spontaneously producing IFNγ was significantly increased after four, but not eight weeks' treatment with etanercept. T cell reactivity, as measured by IFNγ production to PPD, influenza, and CII was significantly increased after four and sustained after eight weeks' treatment, whereas IFNγ production induced by PHA remained unchanged. TNFα production was significantly higher in patients with RA than in controls and did not change during etanercept treatment.
CONCLUSION—Treatment of patients with RA with etanercept may lead to increased peripheral T cell reactivity both to microbial antigens and to self antigens such as CII. These findings indicate that TNFα blockade may not only suppress but also stimulate certain aspects of antimicrobial immune defence and autoimmunity.



Full Text

The Full Text of this article is available as a PDF (173.4 KB).

Figure 1  .

Figure 1  

Open in a new tab

The number of cells spontaneously producing interferon γ (IFNγ) increases after four weeks of treatment with etanercept. The number of IFNγ producing cells/100 000 unstimulated peripheral blood mononuclear cells (PBMC) was enumerated by the ELISPOT method. PBMC from healthy controls (HC, n=17) or patients with RA (n=17) were analysed at baseline and after four and eight weeks of treatment.

Figure 2  .

Figure 2  

Open in a new tab

In vitro antigen reactivity was increased after etanercept treatment. Peripheral blood mononuclear cells (PBMC) were separated from the blood of healthy controls (HC, n=17) or patients with RA (n=17) at baseline and after four and eight weeks of treatment. PBMC were incubated with the microbial derived antigen purified protein derivative (10 µg/ml) (A and B), influenza virus (C), or with collagen type II (100 µg/ml) (D). Supernatants were collected after seven days for the analysis of interferon γ (IFNγ; A, C, and D) and after three days for the analysis of interleukin 2 (IL2) (B). Cytokine measurements were performed using ELISA. Levels of cytokines obtained after incubation without further stimulation (or with acetic acid as a buffer control for collagen type II stimulation) were subtracted.

Figure 3  .

Figure 3  

Open in a new tab

In vitro mitogen reactivity was increased after treatment with etanercept. Peripheral blood mononuclear cells were separated from the blood of healthy controls (HC, n=17) or patients with RA (n=17) at baseline and after four and eight weeks of treatment and incubated with phytohaemagglutinin (5 µg/ml). Supernatants were collected after three days for the analysis of interferon γ (IFNγ) (A) and interleukin 2 (IL2) (B) using ELISA. Levels of cytokine obtained after incubation without further stimulation were subtracted.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allen M. E., Young S. P., Michell R. H., Bacon P. A. Altered T lymphocyte signaling in rheumatoid arthritis. Eur J Immunol. 1995 Jun;25(6):1547–1554. doi: 10.1002/eji.1830250612. [DOI] [PubMed] [Google Scholar]
  2. Arnett F. C., Edworthy S. M., Bloch D. A., McShane D. J., Fries J. F., Cooper N. S., Healey L. A., Kaplan S. R., Liang M. H., Luthra H. S. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988 Mar;31(3):315–324. doi: 10.1002/art.1780310302. [DOI] [PubMed] [Google Scholar]
  3. Berg L., Rönnelid J., Klareskog L., Bucht A. Down-regulation of the T cell receptor CD3 zeta chain in rheumatoid arthritis (RA) and its influence on T cell responsiveness. Clin Exp Immunol. 2000 Apr;120(1):174–182. doi: 10.1046/j.1365-2249.2000.01180.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Berg L., Rönnelid J., Sanjeevi C. B., Lampa J., Klareskog L. Interferon-gamma production in response to in vitro stimulation with collagen type II in rheumatoid arthritis is associated with HLA-DRB1(*)0401 and HLA-DQ8. Arthritis Res. 2000;2(1):75–84. doi: 10.1186/ar71. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Charles P., Elliott M. J., Davis D., Potter A., Kalden J. R., Antoni C., Breedveld F. C., Smolen J. S., Eberl G., deWoody K. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol. 1999 Aug 1;163(3):1521–1528. [PubMed] [Google Scholar]
  6. Cope A. P., Liblau R. S., Yang X. D., Congia M., Laudanna C., Schreiber R. D., Probert L., Kollias G., McDevitt H. O. Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling. J Exp Med. 1997 May 5;185(9):1573–1584. doi: 10.1084/jem.185.9.1573. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Cope A. P., Londei M., Chu N. R., Cohen S. B., Elliott M. J., Brennan F. M., Maini R. N., Feldmann M. Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J Clin Invest. 1994 Aug;94(2):749–760. doi: 10.1172/JCI117394. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Elliott M. J., Maini R. N., Feldmann M., Kalden J. R., Antoni C., Smolen J. S., Leeb B., Breedveld F. C., Macfarlane J. D., Bijl H. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet. 1994 Oct 22;344(8930):1105–1110. doi: 10.1016/s0140-6736(94)90628-9. [DOI] [PubMed] [Google Scholar]
  9. Elliott M. J., Maini R. N., Feldmann M., Long-Fox A., Charles P., Katsikis P., Brennan F. M., Walker J., Bijl H., Ghrayeb J. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum. 1993 Dec;36(12):1681–1690. doi: 10.1002/art.1780361206. [DOI] [PubMed] [Google Scholar]
  10. Emery P., Panayi G. S., Nouri A. M. Interleukin-2 reverses deficient cell-mediated immune responses in rheumatoid arthritis. Clin Exp Immunol. 1984 Jul;57(1):123–129. [PMC free article] [PubMed] [Google Scholar]
  11. Feldmann M. What is the mechanism of action of anti-tumour necrosis factor-alpha antibody in rheumatoid arthritis? Int Arch Allergy Immunol. 1996 Dec;111(4):362–365. doi: 10.1159/000237393. [DOI] [PubMed] [Google Scholar]
  12. Felson D. T., Anderson J. J., Boers M., Bombardier C., Chernoff M., Fried B., Furst D., Goldsmith C., Kieszak S., Lightfoot R. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum. 1993 Jun;36(6):729–740. doi: 10.1002/art.1780360601. [DOI] [PubMed] [Google Scholar]
  13. Hernández-Cruz B., Cardiel M. H., Villa A. R., Alcocer-Varela J. Development, recurrence, and severity of infections in Mexican patients with rheumatoid arthritis. A nested case-control study. J Rheumatol. 1998 Oct;25(10):1900–1907. [PubMed] [Google Scholar]
  14. Higaki M., Miyasaka N., Sato K. Increased expression of CD11b (Mo1) on peripheral blood monocytes of patients with rheumatoid arthritis. J Rheumatol. 1992 May;19(5):825–826. [PubMed] [Google Scholar]
  15. Jacob C. O., Fronek Z., Lewis G. D., Koo M., Hansen J. A., McDevitt H. O. Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor alpha: relevance to genetic predisposition to systemic lupus erythematosus. Proc Natl Acad Sci U S A. 1990 Feb;87(3):1233–1237. doi: 10.1073/pnas.87.3.1233. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Jacob C. O., McDevitt H. O. Tumour necrosis factor-alpha in murine autoimmune 'lupus' nephritis. Nature. 1988 Jan 28;331(6154):356–358. doi: 10.1038/331356a0. [DOI] [PubMed] [Google Scholar]
  17. Kono K., Salazar-Onfray F., Petersson M., Hansson J., Masucci G., Wasserman K., Nakazawa T., Anderson P., Kiessling R. Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell-and natural killer cell-mediated cytotoxicity. Eur J Immunol. 1996 Jun;26(6):1308–1313. doi: 10.1002/eji.1830260620. [DOI] [PubMed] [Google Scholar]
  18. Lai N. S., Lan J. L., Yu C. L., Lin R. H. Role of tumor necrosis factor-alpha in the regulation of activated synovial T cell growth: down-regulation of synovial T cells in rheumatoid arthritis patients. Eur J Immunol. 1995 Dec;25(12):3243–3248. doi: 10.1002/eji.1830251207. [DOI] [PubMed] [Google Scholar]
  19. Maini R., St Clair E. W., Breedveld F., Furst D., Kalden J., Weisman M., Smolen J., Emery P., Harriman G., Feldmann M. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999 Dec 4;354(9194):1932–1939. doi: 10.1016/s0140-6736(99)05246-0. [DOI] [PubMed] [Google Scholar]
  20. Maurice M. M., Lankester A. C., Bezemer A. C., Geertsma M. F., Tak P. P., Breedveld F. C., van Lier R. A., Verweij C. L. Defective TCR-mediated signaling in synovial T cells in rheumatoid arthritis. J Immunol. 1997 Sep 15;159(6):2973–2978. [PubMed] [Google Scholar]
  21. Maurice M. M., van der Graaff W. L., Leow A., Breedveld F. C., van Lier R. A., Verweij C. L. Treatment with monoclonal anti-tumor necrosis factor alpha antibody results in an accumulation of Th1 CD4+ T cells in the peripheral blood of patients with rheumatoid arthritis. Arthritis Rheum. 1999 Oct;42(10):2166–2173. doi: 10.1002/1529-0131(199910)42:10<2166::AID-ANR18>3.0.CO;2-K. [DOI] [PubMed] [Google Scholar]
  22. McHugh S., Deighton J., Rifkin I., Ewan P. Kinetics and functional implications of Th1 and Th2 cytokine production following activation of peripheral blood mononuclear cells in primary culture. Eur J Immunol. 1996 Jun;26(6):1260–1265. doi: 10.1002/eji.1830260612. [DOI] [PubMed] [Google Scholar]
  23. Mitchell D. M., Spitz P. W., Young D. Y., Bloch D. A., McShane D. J., Fries J. F. Survival, prognosis, and causes of death in rheumatoid arthritis. Arthritis Rheum. 1986 Jun;29(6):706–714. doi: 10.1002/art.1780290602. [DOI] [PubMed] [Google Scholar]
  24. Mohler K. M., Torrance D. S., Smith C. A., Goodwin R. G., Stremler K. E., Fung V. P., Madani H., Widmer M. B. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol. 1993 Aug 1;151(3):1548–1561. [PubMed] [Google Scholar]
  25. Moreland L. W., Baumgartner S. W., Schiff M. H., Tindall E. A., Fleischmann R. M., Weaver A. L., Ettlinger R. E., Cohen S., Koopman W. J., Mohler K. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med. 1997 Jul 17;337(3):141–147. doi: 10.1056/NEJM199707173370301. [DOI] [PubMed] [Google Scholar]
  26. Moreland L. W. Inhibitors of tumor necrosis factor for rheumatoid arthritis. J Rheumatol Suppl. 1999 May;57:7–15. [PubMed] [Google Scholar]
  27. Paleolog E. M., Hunt M., Elliott M. J., Feldmann M., Maini R. N., Woody J. N. Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis. Arthritis Rheum. 1996 Jul;39(7):1082–1091. doi: 10.1002/art.1780390703. [DOI] [PubMed] [Google Scholar]
  28. Rood M. J., van Krugten M. V., Zanelli E., van der Linden M. W., Keijsers V., Schreuder G. M., Verduyn W., Westendorp R. G., de Vries R. R., Breedveld F. C. TNF-308A and HLA-DR3 alleles contribute independently to susceptibility to systemic lupus erythematosus. Arthritis Rheum. 2000 Jan;43(1):129–134. doi: 10.1002/1529-0131(200001)43:1<129::AID-ANR16>3.0.CO;2-S. [DOI] [PubMed] [Google Scholar]
  29. Shinohara S., Hirohata S., Inoue T., Ito K. Phenotypic analysis of peripheral blood monocytes isolated from patients with rheumatoid arthritis. J Rheumatol. 1992 Feb;19(2):211–215. [PubMed] [Google Scholar]
  30. Silverman H. A., Johnson J. S., Vaughan J. H., McGlamory J. C. Altered lymphocyte reactivity in rheumatoid arthritis. Arthritis Rheum. 1976 May-Jun;19(3):509–515. doi: 10.1002/art.1780190301. [DOI] [PubMed] [Google Scholar]
  31. Tak P. P., Taylor P. C., Breedveld F. C., Smeets T. J., Daha M. R., Kluin P. M., Meinders A. E., Maini R. N. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum. 1996 Jul;39(7):1077–1081. doi: 10.1002/art.1780390702. [DOI] [PubMed] [Google Scholar]
  32. Taylor P. C., Peters A. M., Paleolog E., Chapman P. T., Elliott M. J., McCloskey R., Feldmann M., Maini R. N. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthritis Rheum. 2000 Jan;43(1):38–47. doi: 10.1002/1529-0131(200001)43:1<38::AID-ANR6>3.0.CO;2-L. [DOI] [PubMed] [Google Scholar]
  33. Torsteinsdóttir I., Arvidson N. G., Hällgren R., Håkansson L. Monocyte activation in rheumatoid arthritis (RA): increased integrin, Fc gamma and complement receptor expression and the effect of glucocorticoids. Clin Exp Immunol. 1999 Mar;115(3):554–560. doi: 10.1046/j.1365-2249.1999.00817.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Ulfgren A. K., Gröndal L., Lindblad S., Khademi M., Johnell O., Klareskog L., Andersson U. Interindividual and intra-articular variation of proinflammatory cytokines in patients with rheumatoid arthritis: potential implications for treatment. Ann Rheum Dis. 2000 Jun;59(6):439–447. doi: 10.1136/ard.59.6.439. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Vercammen C., Ceuppens J. L. Prostaglandin E2 inhibits human T-cell proliferation after crosslinking of the CD3-Ti complex by directly affecting T cells at an early step of the activation process. Cell Immunol. 1987 Jan;104(1):24–36. doi: 10.1016/0008-8749(87)90003-7. [DOI] [PubMed] [Google Scholar]
  36. Verwilghen J., Vertessen S., Stevens E. A., Dequeker J., Ceuppens J. L. Depressed T-cell reactivity to recall antigens in rheumatoid arthritis. J Clin Immunol. 1990 Mar;10(2):90–98. doi: 10.1007/BF00918190. [DOI] [PubMed] [Google Scholar]
  37. Weinblatt M. E., Kremer J. M., Bankhurst A. D., Bulpitt K. J., Fleischmann R. M., Fox R. I., Jackson C. G., Lange M., Burge D. J. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999 Jan 28;340(4):253–259. doi: 10.1056/NEJM199901283400401. [DOI] [PubMed] [Google Scholar]
  38. van Oosten B. W., Barkhof F., Truyen L., Boringa J. B., Bertelsmann F. W., von Blomberg B. M., Woody J. N., Hartung H. P., Polman C. H. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology. 1996 Dec;47(6):1531–1534. doi: 10.1212/wnl.47.6.1531. [DOI] [PubMed] [Google Scholar]
  39. van der Veen M. J., van der Heide A., Kruize A. A., Bijlsma J. W. Infection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate. Ann Rheum Dis. 1994 Apr;53(4):224–228. doi: 10.1136/ard.53.4.224. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES